Impact TMS
Impact Transcranial Magnetic Stimulation (iTMS) is the Neurabello version of accelerated TMS

What is Impact TMS™ for depression and OCD?
Impact Transcranial Magnetic Stimulation (iTMS) is the Neurebello version of accelerated TMS. It is a non-invasive neuromodulation technique developed by CMO Owen Muir. All TMS involves delivering magnetic pulses to specific brain regions, aiming for localized neuronal activation or inhibition. Impact TMS delivers multiple sessions per day to achieve better clinical outcomes in a shorter timeframe with higher durability (how long it lasts).
Currently, Neurobello is focused on iTMS for depression, OCD, and in some cases, PTSD. There are more applications going through the FDA approval process, which we will add in the near future.
Safety of Impact Transcranial Magnetic Stimulation
iTMS is generally well-tolerated with minimal adverse effects. Common side effects include mild headache, scalp discomfort, and transient changes in hearing or vision. The risk of serious adverse events like seizure induction are rare and similar to conventional TMS protocols.
Impact TMS offers a rapid and effective treatment option for psychiatric and neurological conditions. Further research is ongoing to optimize protocols and better understand mechanisms of action. It is considered a safe and efficacious therapeutic intervention in clinical practice.
Outcomes of Impact Transcranial Magnetic Stimulation
-
Significant improvements in depressive symptoms, anxiety, and cognitive function. Studies have shown 79% total remission from all symptoms.
-
Rapid onset of therapeutic effects suitable for patients needing urgent symptom relief or those with treatment-resistant conditions.
What is Impact TMS™ for depression and OCD?
Impact Transcranial Magnetic Stimulation (iTMS) is the Breakthrough6 version of accelerated TMS. It is a non-invasive neuromodulation technique developed by Breakthrough6 founder Owen Muir. All TMS involves delivering magnetic pulses to specific brain regions, aiming for localized neuronal activation or inhibition. Impact TMS delivers multiple sessions per day to achieve better clinical outcomes in a shorter timeframe with higher durability (how long it lasts).
Currently, B6 is focused on iTMS for depression, OCD, and in some cases, PTSD. There are more applications going through the FDA approval process, which we will add in the near future.
Outcomes of Impact Transcranial Magnetic Stimulation
-
Significant improvements in depressive symptoms, anxiety, and cognitive function. Studies have shown 79% total remission from all symptoms
-
Rapid onset of therapeutic effects suitable for patients needing urgent symptom relief or those with treatment-resistant conditions
Safety of Impact Transcranial Magnetic Stimulation
iTMS is generally well-tolerated with minimal adverse effects. Common side effects include mild headache, scalp discomfort, and transient changes in hearing or vision. The risk of serious adverse events like seizure induction are rare and similar to conventional TMS protocols.
Impact TMS offers a rapid and effective treatment option for psychiatric and neurological conditions. Further research is ongoing to optimize protocols and better understand mechanisms of action. It is considered a safe and efficacious therapeutic intervention in clinical practice.

©2024 Breakthrough6 All rights reserved
What is Impact TMS™ for depression and OCD?
Impact Transcranial Magnetic Stimulation (iTMS) is the Breakthrough6 version of accelerated TMS. It is a non-invasive neuromodulation technique developed by Breakthrough6 founder Owen Muir. All TMS involves delivering magnetic pulses to specific brain regions, aiming for localized neuronal activation or inhibition. Impact TMS delivers multiple sessions per day to achieve better clinical outcomes in a shorter timeframe with higher durability (how long it lasts).
Currently, B6 is focused on iTMS for depression, OCD, and in some cases, PTSD. There are more applications going through the FDA approval process, which we will add in the near future.
Safety of Impact Transcranial Magnetic Stimulation
iTMS is generally well-tolerated with minimal adverse effects. Common side effects include mild headache, scalp discomfort, and transient changes in hearing or vision. The risk of serious adverse events like seizure induction are rare and similar to conventional TMS protocols.
Impact TMS offers a rapid and effective treatment option for psychiatric and neurological conditions. Further research is ongoing to optimize protocols and better understand mechanisms of action. It is considered a safe and efficacious therapeutic intervention in clinical practice.
What is Impact TMS™ for depression and OCD?
Impact Transcranial Magnetic Stimulation (iTMS) is the Neurebello version of accelerated TMS. It is a non-invasive neuromodulation technique developed by CMO Owen Muir. All TMS involves delivering magnetic pulses to specific brain regions, aiming for localized neuronal activation or inhibition. Impact TMS delivers multiple sessions per day to achieve better clinical outcomes in a shorter timeframe with higher durability (how long it lasts).
Currently, Neurobello is focused on iTMS for depression, OCD, and in some cases, PTSD. There are more applications going through the FDA approval process, which we will add in the near future.
Safety of Impact Transcranial Magnetic Stimulation
iTMS is generally well-tolerated with minimal adverse effects. Common side effects include mild headache, scalp discomfort, and transient changes in hearing or vision. The risk of serious adverse events like seizure induction are rare and similar to conventional TMS protocols.
Impact TMS offers a rapid and effective treatment option for psychiatric and neurological conditions. Further research is ongoing to optimize protocols and better understand mechanisms of action. It is considered a safe and efficacious therapeutic intervention in clinical practice.
Outcomes of Impact Transcranial Magnetic Stimulation
-
Significant improvements in depressive symptoms, anxiety, and cognitive function. Studies have shown 79% total remission from all symptoms.
-
Rapid onset of therapeutic effects suitable for patients needing urgent symptom relief or those with treatment-resistant conditions.

©2024 Breakthrough6 All rights reserved
Tel. (800) 290-0175
Email: Info@breakthrough6.com